Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) General Information

Description

Global rights to distribution of Camrelizumab for liver cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Shanghai
  • China
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • Shanghai
  • China

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab)‘s full profile, request access.

Request a free trial

Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab)‘s full profile, request access.

Request a free trial

Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) FAQs

  • Where is Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) headquartered?

    Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) is headquartered in Shanghai, China.

  • What industry is Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) in?

    Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab)’s primary industry is Buildings and Property.

  • Is Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) a private or public company?

    Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) is a Private company.

  • What is Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab)’s current revenue?

    The current revenue for Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) is .

  • Who are Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab)’s investors?

    Jiangsu Hengrui Medicine has invested in Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab).

  • When was Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) acquired?

    Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) was acquired on 06-Mar-2024.

  • Who acquired Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab)?

    Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) was acquired by HLB (Holding Companies).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process